Iterum Therapeutics plc (NASDAQ:ITRM – Free Report) – HC Wainwright increased their FY2026 earnings estimates for shares of Iterum Therapeutics in a research report issued on Thursday, June 12th. HC Wainwright analyst M. Keller now expects that the company will earn $0.10 per share for the year, up from their prior forecast of $0.06. HC Wainwright has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Iterum Therapeutics’ current full-year earnings is ($0.86) per share. HC Wainwright also issued estimates for Iterum Therapeutics’ FY2027 earnings at $0.75 EPS.
Iterum Therapeutics (NASDAQ:ITRM – Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.14).
Iterum Therapeutics Stock Performance
Hedge Funds Weigh In On Iterum Therapeutics
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Lee Financial Co acquired a new stake in shares of Iterum Therapeutics during the fourth quarter worth $28,000. Sanctuary Advisors LLC bought a new position in shares of Iterum Therapeutics in the fourth quarter valued at $35,000. Citadel Advisors LLC bought a new position in shares of Iterum Therapeutics in the fourth quarter valued at $38,000. Two Sigma Investments LP bought a new position in shares of Iterum Therapeutics in the fourth quarter valued at $45,000. Finally, OneDigital Investment Advisors LLC bought a new position in shares of Iterum Therapeutics during the first quarter valued at about $124,000. 9.21% of the stock is currently owned by institutional investors and hedge funds.
About Iterum Therapeutics
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.
Recommended Stories
- Five stocks we like better than Iterum Therapeutics
- How to Calculate Options Profits
- Synopsys Stock Falls on China Ban, But Long-Term Outlook Holds
- What is the Dogs of the Dow Strategy? Overview and Examples
- Alphabet Enters a Bull Market: Is It Time to Buy?
- Best Stocks Under $10.00
- Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones
Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.